Samsung Biologics recorded an all-time high revenue in the third quarter of this year, following the previous quarter, as the full-capacity operation of Plants 1 to 4 and U.S. production were reflected in the revenue. The company raised its revenue growth forecast for this year from the previous 15~
Samsung Biologics reported record sales in the third quarter of this year, with full-capacity operation of Plants 1 to 4 and U.S. production contributing to its revenue growth. The company raised its revenue growth forecast for the year from 15-20% to 20%, with consolidated revenue reaching 1.4903 trillion won, an 18% increase from the previous quarter and a 12% increase from the same period last year.
While net profit grew by 9% to 391.1 billion won, the operating profit margin slowed to 43%, down 7% points from the previous year's 50%.
Brief written by urgent.news from BusinessKorea's own syndicated text.
Machine-written — may contain errors; check the original before relying on it.
The family has accused a venture studio CEO of online harassment. The CEO denies the allegation and says he had questioned Harish's financial regulatory credentials.
As early as December, one of the world's most valuable companies could be created by merging SpaceX and Tesla. The most important questions and answers.
